OR WAIT null SECS
The company is developing a pipeline of combination therapies using its patented polymer-based matrix delivery system, known as TAOS (targeted orchestrated signalling matrix).
Locate Therapeutics, a regenerative medicine company based in the United Kingdom, announced on Jan. 18, 2018 that it has successfully achieved EN ISO 13845:2016 certification for the design, development, and control of manufacturing of resorbable injectable tissue scaffolds for use in bone repair and regeneration.
Locate is developing a pipeline of combination therapies using its patented polymer-based matrix as a delivery system. The technology, known as TAOS (targeted orchestrated signalling matrix), is a unique regenerative medicine platform that provides optimal structure to support tissue repair. It can accommodate and promote the actions of locally-applied drugs and emergent biological and cell-based therapies. TAOS injectable particulate formulation is thermally-triggered to solidify into a space-filling open-porous depot that supports tissue repair before degrading away.
Locate is also working on the development of CellFuse, a personalised cell therapy aimed at spinal fusion patients with compromised cell populations. Combining TAOS with another proprietary technology IntraStem, the CellFuse project recently received a Biomedical Catalyst award.
Source: Locate Therapeutics